Vol.52 No.5 May 2004
Efficacy of a therapy switching from amoxicillin to cefditoren pivoxil against a mixed pneumonia model in mice
Infectious Disease Research Laboratories, Meiji Seika Kaisha, Ltd.,
760 Morooka-cho, Kohoku-ku, Yokohama, Kanagawa, Japan
Abstract
We studied the therapeutic efficacy of cefditoren pivoxil (CDTR-PI) and amoxicillin (AMPC) against a mixed pneumonia model of penicillin-susceptible Streptococcus pneumoniae (PSSP) and β -lactamase negative ampicillin resistant Haemophilus influenzae (BLNAR) in mice. The efficacy of CDTR-PI against PSSP was observed at doses of 30 mg/kg/day or higher, and of AMPC at doses of 7.5 mg/kg/day or higher. CDTR-PI treatment against BLNAR also showed therapeutic efficacy at doses of 18.8 mg/kg/day or higher, unlike AMPC. Moreover, the efficacy of a therapy switching from AMPC to CDTR-PI was superior to that of AMPC monotherapy against BLNAR. The effect of switching from AMPC to CFPN-PI and CFDN was approximately equal to that of AMPC monotherapy. This suggests that CDTR-PI is likely to become the drug of choice due to its balanced activity against mixed infection caused by S. pneumoniae and H. influenzae. CDTR-PI is likely to become the drug of second choice in failure of AMPC therapy as the first choice.
Key word
cefditoren pivoxil, amoxicillin, mixed lung infection, β-lactamase negative ampicillin resistant Haemophilus influenzae, oral cephems
Received
March 1, 2004
Accepted
April 22, 2004
Jpn. J. Chemother. 52 (5): 251-255, 2004
